semaglutide mastery course
Unit 4 of 12

obesity and weight management

STEP trials, appetite circuits, and the science behind sustained weight loss.

the weight loss mechanism

This unit covers how semaglutide reduces appetite through hypothalamic and brainstem pathways, slows gastric emptying to increase satiety, and the landmark STEP trial program that demonstrated 15-18.7% mean body weight reduction at 68 weeks, forming the evidentiary basis for FDA approval of chronic weight management.

Interactive Dashboard

Visualize energy balance shifts and weight trajectories across clinical trials.

energy balance and weight loss dashboard
-14.9%
mean body weight reduction in STEP 1 (n=1,961) at 68 weeks vs -2.4% with placebo -- the result that earned the obesity indication
20-35%
reduction in caloric intake driven by hypothalamic appetite suppression and altered food reward signaling
2/3
proportion of weight regained within one year of discontinuation -- the durability challenge that defines long-term treatment planning
-18.7%
weight loss at the higher 7.2 mg dose in STEP UP -- suggesting the dose-response curve had not plateaued at the approved 2.4 mg
weight regain is the rule, not the exception. The STEP 1 extension data showed that roughly two-thirds of weight lost was regained within a year of stopping semaglutide. This does not mean the drug "stopped working" -- it means obesity is a chronic condition requiring ongoing treatment, similar to hypertension or diabetes. Discontinuation planning is covered in the dosing unit.

key terms for this unit

S STEP trial program clinical evidence
The Semaglutide Treatment Effect in People with Obesity program -- a series of phase 3 trials (STEP 1 through STEP 5+) that tested 2.4 mg weekly semaglutide for chronic weight management. STEP 1 enrolled 1,961 adults without diabetes, STEP 2 included adults with T2D, and later trials tested higher doses (STEP UP) and long-term maintenance.
G gastric emptying delay GI physiology
Semaglutide slows gastric emptying by 10-30%, which contributes to early satiety and reduced portion sizes. However, this effect shows tachyphylaxis (diminishing over time), suggesting it is not the primary long-term weight loss mechanism -- the central appetite suppression through hypothalamic and brainstem pathways sustains the effect.
P POMC neurons neuroscience
Pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus that produce alpha-MSH, a potent appetite-suppressing signal. GLP-1R activation stimulates POMC neurons while simultaneously inhibiting AgRP/NPY neurons (which drive hunger), creating a dual push-pull effect on energy intake.
S set point theory obesity science
The hypothesis that the body defends a particular weight range through hormonal feedback loops (leptin, ghrelin, GLP-1, etc.). The 2/3 weight regain after semaglutide discontinuation is consistent with this model -- removing the pharmacological override allows the defended set point to reassert itself through increased hunger and metabolic adaptation.
F food reward modulation behavioral neuroscience
Beyond caloric reduction, semaglutide users report decreased cravings for high-fat and high-sugar foods. Neuroimaging studies suggest GLP-1R agonism reduces activity in mesolimbic reward circuits (ventral tegmental area, nucleus accumbens), which may explain the reported decrease in alcohol consumption and addictive-behavior reduction observed in some patients.

why appetite suppression alone does not explain 15% weight loss

The 20-35% reduction in caloric intake accounts for most of the early weight loss, but semaglutide likely does more than just reduce hunger. gastric emptying slows by 10-30% in the first weeks, reducing meal sizes through mechanical fullness. food reward circuits in the brain are dampened, shifting dietary preferences away from calorie-dense foods. and there is emerging evidence for modest effects on energy expenditure, though the data here is less clear.

The durability question is equally important. STEP 1 showed -14.9% at 68 weeks, but the extension data revealed that approximately two-thirds of that weight returned within a year of stopping. this is not a failure of the drug -- it is the expected biological response when a chronic hormonal override is removed. STEP UP explored whether higher doses (7.2 mg) could push weight loss further, achieving -18.7%, and trials are ongoing to determine whether combination approaches can reduce the regain problem.